These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 25184245)
21. Identification and characterization of a cathepsin K homologue that interacts with pathogen bacteria in black rockfish, Sebastes schlegelii. He SW; Du X; Wang GH; Wang JJ; Xie B; Gu QQ; Zhang M; Gu HJ Fish Shellfish Immunol; 2020 Mar; 98():499-507. PubMed ID: 32001355 [TBL] [Abstract][Full Text] [Related]
22. Green asymmetric synthesis of epoxypeptidomimetics and evaluation as human cathepsin K inhibitors. Silva TL; Dos Santos DA; de Jesus HCR; Brömme D; Fernandes JB; Paixão MW; Corrêa AG; Vieira PC Bioorg Med Chem; 2020 Aug; 28(15):115597. PubMed ID: 32631567 [TBL] [Abstract][Full Text] [Related]
23. Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L. Falgueyret JP; Oballa RM; Okamoto O; Wesolowski G; Aubin Y; Rydzewski RM; Prasit P; Riendeau D; Rodan SB; Percival MD J Med Chem; 2001 Jan; 44(1):94-104. PubMed ID: 11141092 [TBL] [Abstract][Full Text] [Related]
24. Cathepsin K deficiency in mice induces structural and metabolic changes in the central nervous system that are associated with learning and memory deficits. Dauth S; Sîrbulescu RF; Jordans S; Rehders M; Avena L; Oswald J; Lerchl A; Saftig P; Brix K BMC Neurosci; 2011 Jul; 12():74. PubMed ID: 21794126 [TBL] [Abstract][Full Text] [Related]
25. Efficient processing of procathepsin K to the mature form. Emmott AA; Mort JS Protein Expr Purif; 2013 Sep; 91(1):37-41. PubMed ID: 23845403 [TBL] [Abstract][Full Text] [Related]
26. The role of basic amino acid surface clusters on the collagenase activity of cathepsin K. Nallaseth FS; Lecaille F; Li Z; Brömme D Biochemistry; 2013 Nov; 52(44):7742-52. PubMed ID: 24088021 [TBL] [Abstract][Full Text] [Related]
27. Advances in the discovery of cathepsin K inhibitors on bone resorption. Lu J; Wang M; Wang Z; Fu Z; Lu A; Zhang G J Enzyme Inhib Med Chem; 2018 Dec; 33(1):890-904. PubMed ID: 29723068 [TBL] [Abstract][Full Text] [Related]
28. Pharmacological inhibition of cathepsin K: A promising novel approach for postmenopausal osteoporosis therapy. Mukherjee K; Chattopadhyay N Biochem Pharmacol; 2016 Oct; 117():10-9. PubMed ID: 27106079 [TBL] [Abstract][Full Text] [Related]
29. Orally bioavailable cathepsin K inhibitors with pyrrolopyrimidine scaffold. Teno N; Masuya K Curr Top Med Chem; 2010; 10(7):752-66. PubMed ID: 20337583 [TBL] [Abstract][Full Text] [Related]
30. Inhibition of the cathepsin cysteine proteases B and K by square-planar cycloaurated gold(III) compounds and investigation of their anti-cancer activity. Zhu Y; Cameron BR; Mosi R; Anastassov V; Cox J; Qin L; Santucci Z; Metz M; Skerlj RT; Fricker SP J Inorg Biochem; 2011 May; 105(5):754-62. PubMed ID: 21481817 [TBL] [Abstract][Full Text] [Related]
31. Fast profiling of protease specificity reveals similar substrate specificities for cathepsins K, L and S. Vizovišek M; Vidmar R; Van Quickelberghe E; Impens F; Andjelković U; Sobotič B; Stoka V; Gevaert K; Turk B; Fonović M Proteomics; 2015 Jul; 15(14):2479-90. PubMed ID: 25626674 [TBL] [Abstract][Full Text] [Related]
32. Design of potent and selective human cathepsin K inhibitors that span the active site. Thompson SK; Halbert SM; Bossard MJ; Tomaszek TA; Levy MA; Zhao B; Smith WW; Abdel-Meguid SS; Janson CA; D'Alessio KJ; McQueney MS; Amegadzie BY; Hanning CR; DesJarlais RL; Briand J; Sarkar SK; Huddleston MJ; Ijames CF; Carr SA; Garnes KT; Shu A; Heys JR; Bradbeer J; Zembryki D; Lee-Rykaczewski L; James IE; Lark MW; Drake FH; Gowen M; Gleason JG; Veber DF Proc Natl Acad Sci U S A; 1997 Dec; 94(26):14249-54. PubMed ID: 9405598 [TBL] [Abstract][Full Text] [Related]
33. A novel class of nonpeptidic biaryl inhibitors of human cathepsin K. Robichaud J; Oballa R; Prasit P; Falgueyret JP; Percival MD; Wesolowski G; Rodan SB; Kimmel D; Johnson C; Bryant C; Venkatraman S; Setti E; Mendonca R; Palmer JT J Med Chem; 2003 Aug; 46(17):3709-27. PubMed ID: 12904076 [TBL] [Abstract][Full Text] [Related]
34. 6. Cathepsin K inhibitors: their potential as anti-osteoporosis agents. Deaton DN; Kumar S Prog Med Chem; 2004; 42():245-375. PubMed ID: 15003723 [No Abstract] [Full Text] [Related]
35. Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin k. Tavares FX; Boncek V; Deaton DN; Hassell AM; Long ST; Miller AB; Payne AA; Miller LR; Shewchuk LM; Wells-Knecht K; Willard DH; Wright LL; Zhou HQ J Med Chem; 2004 Jan; 47(3):588-99. PubMed ID: 14736240 [TBL] [Abstract][Full Text] [Related]
36. Cathepsin K inhibitors: a novel target but promising approach in the treatment of osteoporosis. Helali AM; Iti FM; Mohamed IN Curr Drug Targets; 2013 Dec; 14(13):1591-600. PubMed ID: 23957815 [TBL] [Abstract][Full Text] [Related]
37. Soluble cathepsin K: a novel marker for the prediction of nontraumatic fractures? Holzer G; Noske H; Lang T; Holzer L; Willinger U J Lab Clin Med; 2005 Jul; 146(1):13-7. PubMed ID: 16025086 [TBL] [Abstract][Full Text] [Related]
38. Human cathepsin L, a papain-like collagenase without proline specificity. Korenč M; Lenarčič B; Novinec M FEBS J; 2015 Nov; 282(22):4328-40. PubMed ID: 26306868 [TBL] [Abstract][Full Text] [Related]
39. Effect of cathepsin k inhibitor basicity on in vivo off-target activities. Desmarais S; Black WC; Oballa R; Lamontagne S; Riendeau D; Tawa P; Duong LT; Pickarski M; Percival MD Mol Pharmacol; 2008 Jan; 73(1):147-56. PubMed ID: 17940194 [TBL] [Abstract][Full Text] [Related]
40. Collagenolytic activity of cathepsin K is specifically modulated by cartilage-resident chondroitin sulfates. Li Z; Hou WS; Brömme D Biochemistry; 2000 Jan; 39(3):529-36. PubMed ID: 10642177 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]